Ertapenem (Invanz)

A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.

Also Known As:

Networked: 539 relevant articles (86 outcomes, 135 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Woods, Gail L: 19 articles (06/2004 - 01/2002)
2.	Abramson, Murray A: 11 articles (04/2009 - 08/2005)
3.	Teppler, Hedy: 11 articles (08/2005 - 01/2002)
4.	Gesser, Richard M: 11 articles (06/2004 - 01/2002)
5.	Hsueh, Po-Ren: 9 articles (06/2022 - 05/2011)
6.	Ko, Wen-Chien: 9 articles (06/2022 - 11/2010)
7.	Nicolau, David P: 9 articles (01/2022 - 01/2005)
8.	Goldstein, Ellie J C: 9 articles (04/2009 - 04/2002)
9.	Citron, Diane M: 8 articles (04/2009 - 04/2002)
10.	Lipsky, Benjamin A: 7 articles (01/2020 - 06/2004)

Related Diseases

1.	Infections 06/01/2014 - "This study has shown that ertapenem is not a suitable alternative for first-line treatment for gonorrhoea but that it may be useful for the treatment of highly resistant infections." 01/01/2014 - "Ertapenem has been demonstrated to be highly effective for the treatment of complicated infections. " 07/01/2010 - "Ertapenem administration through OPAT may help to decrease the costs associated with ESBL infections by reducing the number of inpatient bed days required for their successful treatment." 01/01/2021 - "The in vitro results suggest that ertapenem has satisfactory susceptibility in isolates collected from eight provinces in China; hence, it might be a promising treatment option for resistant gonococcal infections." 06/06/2007 - "Clinical outcomes studies are needed to determine if ertapenem is effective for the treatment of infection caused by these organisms. "
2.	Pneumonia (Pneumonitis) 01/01/2017 - "Future studies are needed to investigate ertapenem efficacy against ESBL-producing Enterobacteriaceae pneumonia to determine its applicability in life-threatening conditions. " 01/01/2022 - "The objective of this study was to compare the rate of pneumonia resolution in obese (body mass index [BMI], ≥30 kg/m2) and nonobese (BMI, <30 kg/m2) patients treated with 1 gram ertapenem daily. " 02/01/2016 - "Few studies examined ertapenem for the treatment of pneumonia. " 01/01/2022 - "Outcomes were similar in obese and nonobese patients treated with 1 gram of ertapenem daily for pneumonia." 01/01/2022 - "Patients were included if they were between 18 and 89 years old and received ertapenem for at least 48 hours for pneumonia treatment. "
3.	Urinary Tract Infections (Urinary Tract Infection) 09/01/2014 - "The objective of this study was to determine the pharmacokinetics and renal disposition of ertapenem in outpatients with complicated urinary tract infections. " 10/01/2019 - "Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection." 01/01/2017 - "Ertapenem for multiple β-lactamases producing Gram-negative bacteria causing urinary tract infections in HIV patients." 12/01/2015 - "All patients received renal adjusted doses of ertapenem for complicated urinary tract infection (UTI). " 01/01/2015 - "The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children."
4.	Intraabdominal Infections 01/01/2003 - "[Efficacy of invanz proven in the treatment of intra-abdominal infections in one of the largest studies yet conducted on surgical patients]." 06/01/2013 - "The Study for Monitoring Antimicrobial Resistance Trends has monitored the in vitro activity of ertapenem and several comparators against aerobic gram-negative bacteria from intra-abdominal infections (IAIs) for many years. " 04/01/2013 - "The Study for Monitoring Antimicrobial Resistance Trends (SMART) has tracked the in vitro activity of ertapenem and comparators against aerobic gram-negative bacteria from intra-abdominal infections since 2002. " 12/01/2011 - "Antimicrobial susceptibility data from the SMART-Spain study reinforce current therapeutic guidelines of intraabdominal infections that include ertapenem as the empirical choice for treatment. " 05/01/2008 - "No difference was found between adult patients with complicated intra-abdominal infections treated with ertapenem vs. comparators, regarding clinical success (five randomized-controlled trials, 2002 patients, fixed-effect model, odds ratio: 1.11, 95% confidence interval (CI): 0.89-1.39); clinical adverse events (four randomized-controlled trials, 1530 patients, fixed-effect model, OR: 0.86, 95% CI: 0.61-1.20); microbiological success; mortality and withdrawals because of adverse events. "
5.	Bacteremia 04/01/2012 - "The object of this study was to investigate the risk factors, characteristics and outcomes of ertapenem-nonsusceptible K pneumoniae (ENSKp) bacteremia. " 12/01/2020 - "He experienced a recurrence of bacteremia without a clear source and was successfully treated with 10 weeks of intravenous ertapenem. " 01/01/2017 - "We presented three cases who were successfully treated with addition of ertapenem to the combination treatment for bacteremia with multidrug resistant Klebsiella pneumoniae. " 04/01/2012 - "The controls were randomly selected among patients with ertapenem-susceptible K pneumoniae (ESKp) bacteremia and were matched with ENSKp cases for bacteremia. " 04/01/2012 - "Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study."

Related Drugs and Biologics

1.	Tazobactam Drug Combination Piperacillin (Zosyn)
2.	Ceftriaxone (Ceftriaxon)
3.	Carbapenems (Carbapenem Antibiotics)
4.	Anti-Bacterial Agents (Antibiotics)
5.	Meropenem (Merrem)
6.	Cefepime (Maxipime)
7.	Imipenem
8.	Cefazolin (Ancef)
9.	beta-Lactamases (beta-Lactamase)
10.	Methicillin (Metin)

Related Therapies and Procedures

1.	Therapeutics
2.	Punctures
3.	Ligation
4.	Biological Therapy
5.	Fecal Microbiota Transplantation